Menu

Pharmaceuticals

Allergan Successfully Completes ZELTIQ® Aesthetics Acquisition

, , , ,

Acquisition Adds Best-in-Class Body Contouring Business to Allergan’s World-Class Facial Aesthetics, Plastic Surgery & Regenerative Medicine Businesses Acquisition of CoolSculpting,® Sales Leader in Fast-Growing, Cash Pay Body Contouring Segment, is Immediately Accretive to Allergan DUBLIN, April 28, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced it has successfully completed […]

Supervisory Board of Bayer AG extends service contract of CFO Johannes Dietsch to the end of May 2018

, , , ,

Leverkusen, April 27, 2017 – The Supervisory Board of Bayer AG has extended the current service contract of Chief Financial Officer Johannes Dietsch (55) until May 31, 2018. After that date, Johannes Dietsch will be leaving the company at his own request. “Designing the detailed financing of the Monsanto acquisition and the ongoing approval and […]

Abbott Introduces Science-based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery

, , , ,

Research shows that staying nourished in the days and hours prior to a procedure can help patients prepare for and recover from surgery New Ensure® Surgery Immunonutrition Shake and Ensure® Pre-Surgery Clear Nutrition Drink are designed for hospitals implementing surgical guidelines for enhancing patient recovery ABBOTT PARK, Ill., April 26, 2017 /PRNewswire/ — More than […]

Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production

, , , ,

First-of-its-Kind Product Further Adds to Allergan’s Robust Eye Care Portfolio DUBLIN, April 25, 2017 /PRNewswire/ — Allergan plc, (NYSE: AGN) today announced that it has been granted marketing authorization from the U.S. Food and Drug Administration (FDA) for TrueTear™ Intranasal Tear Neurostimulator, the first and only FDA-cleared device developed to temporarily increase tear production during […]

America’s Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community

, , , , ,

Merck, the American Diabetes Association and Celebrity Voices Offer Tips to Help People Tackle Their Obstacles Head On KENILWORTH, N.J. April 25, 2017 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as […]

Johnson & Johnson Human Performance Institute Launches Corporate Athlete® Resilience Program

, , ,

Training solution addresses corporate burnout, managing uncertainty, stress awareness, and strategic recovery NEW BRUNSWICK, N.J., April 25, 2017 – Johnson & Johnson Human Performance Institute (JJHPI) announced the launch of Corporate Athlete® Resilience, a new in-depth training solution that takes a different approach to stress management by supporting an individual’s ability to redefine and strategically […]

Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis

, , ,

The Phase 3 study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in patients with HR+, HER2- advanced breast cancer INDIANAPOLIS, April 24, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating […]

Bayer partners with Goodbye Malaria to help “End Malaria for Good”

, , , ,

Monheim, April 24, 2017 – Bayer announces the establishment of a partnership with Goodbye Malaria. Both organizations will jointly support the objectives of Ending Malaria for Good in Southern Africa. The figures published in the 2016 WHO malaria report, with malaria cases falling by 21 percent between 2010 and 2015 and malaria death rates falling […]

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C

, , , , ,

Findings Presented at The International Liver Congress™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed KENILWORTH, N.J. April 22, 2017 –(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) […]

Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C

, , , , ,

Study Evaluated VA Population with High Incidence of Co-Morbidities KENILWORTH, N.J. April 21, 2017 –(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered ZEPATIER® in the U.S. […]

‹ 1 2 3 4›»